Products for Research Use Only
RegisterLogin

Everolimus-d4

CAT: 0804-HY-10218S-01Size: 500 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10218S-01Size:500 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Everolimus-d4 is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].
CAS Number
1338452-54-2
Product Name Alternative
RAD001-d4; SDZ-RAD-d4
UNSPSC
12352005
Hazard Statement
H372
Target
Apoptosis; Autophagy; FKBP; mTOR
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; PI3K/Akt/mTOR
Field of Research
Cancer
Purity
98.74
Solubility
10 mM in DMSO
Smiles
O=C1N2[C@](CCCC2)([H])C(O[C@](CC([C@@H](/C=C([C@H]([C@H](C([C@@H](C[C@@H](/C=C/C=C/C=C([C@H](C[C@@]3([H])O[C@@](C1=O)([C@@H](CC3)C)O)OC)\C)C)C)=O)OC)O)\C)C)=O)([H])[C@H](C)C[C@H]4C[C@H]([C@@H](CC4)OC([2H])([2H])C([2H])([2H])O)OC)=O
Molecular Formula
C53H79D4NO14
Molecular Weight
962.25
Precautions
H372
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Lane HA, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res, 2009, 15 (5), 1612-1622.|[3]O'Reilly T, et al. Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001) : Processes, Limitations, and Further Proposals. Transl Oncol. 2010 Apr;3 (2) :65-79.|[4]Zhu Y, et al. Antitumor effect of the mTOR inhibitor Everolimus on human breast cancer stem cells in vitro and in vivo. Tumour Biol. 2012 Oct;33 (5) :1349-62.|[5]Kawata T, et al. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia. Cancer Sci. 2018 Jan;109 (1) :103-111.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-10218S1Everolimus-13C2, d4
HY-10218-01Everolimus
HY-10218R-01Everolimus (Standard)
HY-151912S-01Picolinafen-d4 (4-Fluorophenyl-d4)
HY-132468SKeto Pioglitazone-d4 (M-III-d4)
HY-151892SGlimepiride-d4 (phenylethyl-α, α, β, β-d4) (cis/trans)
HY-W654154Dexmedetomidine-d4 L-tartrate (-d4-major)
HY-151910S(±) -Fluoxetine-d4 Oxalate (trifluoromethylphen-d4-oxy)
HY-113313S2Aldosterone-d4
HY-15731SEstetrol-d4

Alternative Products

CatalogName
011893Everolimus-d4
TRC-E945402-1MGEverolimus-d4 (~90%)
AR-E02255-01Everolimus-13C2-d4
449864-01Everolimus-13C2, D4 discontinued
42146228-Ethylhydroxy Everolimus-d4 Impurity
FE23209-01Everolimus

Popular Products